AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7114867 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial stripping of the stratum corneum
Number of subjects: 159
Study 7114867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 159
Study 31802616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (SITA) 100 mg qd
Number of subjects: 40
Study 31802616 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 850 mg bid
Number of subjects: 40
Study 31802616 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Sitagliptin (MET+SITA) 50 + 850 mg bid
Number of subjects: 40
Study 31471037 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (LT) 50 mg
Number of subjects: 70
Study 31471037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29948456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 660- and 808-nm wavelengths low-level laser therapy (LLLT) (300 J/cm2, 9 J of total energy, 100 mW, spot size 3 mm2), performed twice a week.
Number of subjects: 0
Study 29948456 — intervention group
Group type: COMPARATOR
Intervention: 660-nm wavelength low-level laser therapy (LLLT) (300 J/cm2, 9 J of total energy, 100 mW, spot size 3 mm2), performed twice a week.
Number of subjects: 0
Study 26373826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleth Variability Index (PVI)
Number of subjects: 75
Study 26373826 — intervention group
Group type: COMPARATOR
Intervention: Doppler
Number of subjects: 75
Study 25187257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (vitamin C) 10 mg/kg/day and α-tocopherol (vitamin E) 10 mg/kg/day
Number of subjects: 0
Study 25187257 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 25187257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid and α-tocopherol
Number of subjects: 0
Study 22342027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral self-help program (SHP) combined with pharmacotherapy
Number of subjects: 80
Study 22342027 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (control)
Number of subjects: 80
Study 20228402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (up to 60 mg three times daily)
Number of subjects: 9306
Study 20228402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study 17491259 — intervention group
Group type: EXPERIMENTAL
Intervention: FASL‐844 TT genotype
Number of subjects: 184
Study 17491259 — intervention group
Group type: COMPARATOR
Intervention: FASL‐844 CT and TT genotypes
Number of subjects: 184
Study 15797672 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pyruvate (PYR) 5 g twice daily for 30 days
Number of subjects: 23
Study 15797672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study 11965274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 170432
Study 11965274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not contacted)
Number of subjects: 170432
Study 9927844 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0
Study 9927844 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (t-PA)
Number of subjects: 0
Study 8713941 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste
Number of subjects: 143
Study 8713941 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control toothpaste
Number of subjects: 143
Study 8713941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsodent Ultra toothpaste
Number of subjects: 143
Study 8713941 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 143
Study 2669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 400 micrograms
Number of subjects: 128
Study 2669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms
Number of subjects: 128
Study 2669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 400 micrograms
Number of subjects: 128
Study 2669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 800 micrograms
Number of subjects: 128
Study 2669554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 2669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 128
Study 365774 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose subunit vaccine (2100 IU)
Number of subjects: 399
Study 365774 — intervention group
Group type: COMPARATOR
Intervention: Whole virus vaccine (2100 IU)
Number of subjects: 399
Study 365774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose subunit vaccine (700 IU)
Number of subjects: 399
Study 365774 — intervention group
Group type: COMPARATOR
Intervention: Split virus adjuvant vaccine (800 IU with AI(OH)3)
Number of subjects: 399
Study 30580896 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic 3D immersive video exposure-based treatment (six 5-minute exposures)
Number of subjects: 77
Study 30580896 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation only control condition (30-minute neutral video, 2D documentary)
Number of subjects: 77
Study 28528565 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Conservation Management (ECM) intervention
Number of subjects: 86
Study 28528565 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 86
Study 26037907 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium tacks
Number of subjects: 220
Study 26037907 — intervention group
Group type: COMPARATOR
Intervention: Absorbable tacks
Number of subjects: 220
Study 23696200 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion training
Number of subjects: 0
Study 21652734 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 254
Study 21652734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 19225061 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental live reactive telephone counseling (n = 494)
Number of subjects: 990
Study 19225061 — intervention group
Group type: COMPARATOR
Intervention: Mailed self-help literature (n = 496)
Number of subjects: 990
Study 16455419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast agent (UCA) Optison
Number of subjects: 12
Study 16455419 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast agents (Optison, Sonovue, Sonazoid)
Number of subjects: 12
Study 15762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley prosthesis
Number of subjects: 129
Study 15762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubinus IP
Number of subjects: 129
Study 15762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Other cemented implants
Number of subjects: 129
Study 15762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented stems
Number of subjects: 129
Study 11775045 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-50 mg/day)
Number of subjects: 307
Study 11775045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 9400355 — intervention group
Group type: EXPERIMENTAL
Intervention: Total quality improvement methods
Number of subjects: 17324
Study 8214276 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine treatment
Number of subjects: 224
Study 3593451 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride (2 X 0.2 mg/d per os)
Number of subjects: 15
Study 3593451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28635526 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling on diet, physical activity, and weight management from trained nurses at six timepoints and three meetings with a dietitian
Number of subjects: 266
Study 28635526 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 266
Study 28635526 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling on diet, physical activity, and weight management
Number of subjects: 266
Study 27206567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg QD
Number of subjects: 1438
Study 27206567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Number of subjects: 1438
Study 27206567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1438
Study 27206567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin and prohibited serotonergic agents
Number of subjects: 1438
Study 27206567 — intervention group
Group type: COMPARATOR
Intervention: Placebo and prohibited serotonergic agents
Number of subjects: 1438
Study 24655769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based counselling intervention for depression adapted from Interpersonal Therapy (IPT)
Number of subjects: 34
Study 24655769 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 24655769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based counselling intervention for depression
Number of subjects: 34
Study 23291605 — intervention group
Group type: EXPERIMENTAL
Intervention: PrT with dextrose
Number of subjects: 26
Study 23291605 — intervention group
Group type: EXPERIMENTAL
Intervention: PrT with dextrose-morrhuate sodium
Number of subjects: 26
Study 23291605 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see
Number of subjects: 26
Study 19730952 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Stretta (Group A)
Number of subjects: 36
Study 19730952 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose Stretta (Group C)
Number of subjects: 36
Study 19730952 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Group B)
Number of subjects: 36
Study 18762804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 357
Study 18762804 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (DSE)
Number of subjects: 357
Study 18762804 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse weight loss
Number of subjects: 357
Study 17116917 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multicomponent intervention addressing caregiver depression, burden, self-care, and social support through 12 in-home and telephone sessions over 6 months.
Number of subjects: 642
Study 17116917 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multicomponent intervention
Number of subjects: 642
Study 17116917 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 2 brief 'check-in' telephone calls during the 6-month intervention.
Number of subjects: 642
Study 14648126 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta20% priming exercise
Number of subjects: 8
Study 14648126 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta40% priming exercise
Number of subjects: 8
Study 14648126 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta60% priming exercise
Number of subjects: 8
Study 14648126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-lactate threshold (LT) at 80% of LT
Number of subjects: 8
Study 14648126 — intervention group
Group type: COMPARATOR
Intervention: No warm-up control (CON)
Number of subjects: 8
Study 11710785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 61
Study 11710785 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 61
Study 9203723 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) administered at 2 and 3 months of age followed by doses of both IPV and oral poliovirus vaccine (OPV) at 4 and 9 months of age
Number of subjects: 16566
Study 8291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg 3 times daily for 2 weeks
Number of subjects: 41
Study 8291408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3561773 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin
Number of subjects: 22
Study 3561773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30929011 — intervention group
Group type: EXPERIMENTAL
Intervention: % inorganic arsenic in urine
Number of subjects: 12609
Study 30929011 — intervention group
Group type: EXPERIMENTAL
Intervention: % monomethylarsenate in urine
Number of subjects: 12609
Study 30929011 — intervention group
Group type: EXPERIMENTAL
Intervention: % dimethylarsinate in urine
Number of subjects: 12609
Study 29274643 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition protocol
Number of subjects: 90
Study 29274643 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (Control)
Number of subjects: 90
Study 26253175 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET)
Number of subjects: 68
Study 26253175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68
Study 26253175 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 68
Study 24839241 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5mg yearly infusion
Number of subjects: 1486
Study 24839241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1486
Study 22153327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO‐OP) intervention
Number of subjects: 13
Study 22153327 — intervention group
Group type: COMPARATOR
Intervention: Contemporary treatment or task-specific training
Number of subjects: 13
Study 22153327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Performance Analysis (DPA)
Number of subjects: 13
Study 20505273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral or recurrent lesions of ocular adnexal lymphoma
Number of subjects: 10
Study 20505273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral orbital lesions, rectum, and stomach lesions
Number of subjects: 10
Study 20505273 — intervention group
Group type: EXPERIMENTAL
Intervention: Original and recurrent conjunctival lesions
Number of subjects: 10
Study 20505273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral orbital or conjunctival lesions
Number of subjects: 10
Study 20505273 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital lesion and oral cavity lesion
Number of subjects: 10
Study 20505273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral orbital lesions, buccal, rectum, and stomach lesions
Number of subjects: 10
Study 17490954 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) at a dose of 3.2 g/d
Number of subjects: 18
Study 17490954 — intervention group
Group type: COMPARATOR
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 18
Study 16308498 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-guided PV isolation
Number of subjects: 100
Study 16308498 — intervention group
Group type: COMPARATOR
Intervention: CC-guided PV isolation
Number of subjects: 100
Study 12184034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial therapy
Number of subjects: 0
Study 9805696 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional approach (blind placement through the larynx)
Number of subjects: 58
Study 9805696 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed approach (intubation under direct vision using fiberoptic bronchoscope)
Number of subjects: 58
Study 7615916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 0
Study 7615916 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0
Study 7615916 — intervention group
Group type: COMPARATOR
Intervention: Stress management interventions (general)
Number of subjects: 0
Study 2792753 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut food challenge
Number of subjects: 71
Study 770226 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (R)‐15‐methyl PGE2 methyl ester
Number of subjects: 32
Study 770226 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (S)‐15‐methyl PGE2 methyl ester
Number of subjects: 32
Study 770226 — intervention group
Group type: EXPERIMENTAL
Intervention: 16, 16‐dimethyl PGE2
Number of subjects: 32
Study 770226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31394600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 71
Study 31394600 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 71
Study 27541997 — intervention group
Group type: EXPERIMENTAL
Intervention: Total atrial conduction time (TACT) measured by PA‐TDI interval via echocardiography
Number of subjects: 90
Study 27541997 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc score
Number of subjects: 90
Study 27541997 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer PA‐TDI interval
Number of subjects: 90
Study 25361685 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported medication non-adherence
Number of subjects: 405
Study 25361685 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 405
Study 25361685 — intervention group
Group type: EXPERIMENTAL
Intervention: Life chaos score
Number of subjects: 405
Study 25361685 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about stroke
Number of subjects: 405
Study 23183356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrothricin 0.1% gel
Number of subjects: 33
Study 23183356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle gel
Number of subjects: 33
Study 23183356 — intervention group
Group type: COMPARATOR
Intervention: Untreated test fields
Number of subjects: 33
Study 21450978 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)‐adjuvanted H1N1 vaccine containing 3.75 μg hemagglutinin (HA)
Number of subjects: 261
Study 21450978 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1 vaccine containing 15 μg HA
Number of subjects: 261
Study 21450978 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1 vaccine containing 3.75 μg HA
Number of subjects: 261
Study 21450978 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A) adjuvant
Number of subjects: 261
Study 18649012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer (5 x 10(9) pfu)
Number of subjects: 18
Study 18649012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer (1 x 10(10) pfu)
Number of subjects: 18
Study 18649012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer (2 x 10(10) pfu)
Number of subjects: 18
Study 18649012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer
Number of subjects: 18
Study 17892986 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (EPO) for 4 months followed by maintenance for another 8 months, with oral iron throughout 12 months.
Number of subjects: 51
Study 17892986 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline as placebo and oral iron throughout 12 months.
Number of subjects: 51
Study 15471829 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed 18F‐FDG PET imaging
Number of subjects: 19
Study 15471829 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-time data analysis
Number of subjects: 19
Study 11561827 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg of intravaginal misoprostol every 12 hours
Number of subjects: 143
Study 11561827 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of intravaginal misoprostol every 12 hours
Number of subjects: 143
Study 9773717 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Insulin Pump (IIP) therapy
Number of subjects: 121
Study 9773717 — intervention group
Group type: COMPARATOR
Intervention: Multiple-Dose Insulin (MDI) therapy
Number of subjects: 121
Study 9773717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 121
Study 8148225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (100 mg elemental iron) with norfloxacin (400 mg)
Number of subjects: 8
Study 8148225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (100 mg elemental iron) with ciprofloxacin (500 mg)
Number of subjects: 8
Study 8148225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (100 mg elemental iron) with ofloxacin (400 mg)
Number of subjects: 8
Study 3167505 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritendonous injection of 40 mgs of methyl prednisolone acetate (Depo Medrone)
Number of subjects: 28
Study 3167505 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of 0.25% marcaine alone
Number of subjects: 28
Study 4943606 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 717
Study 4943606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 31874736 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Therapy (GDFT) using non-invasive cardiac output monitoring for 12 hours
Number of subjects: 60
Study 31874736 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 60
Study 31874736 — intervention group
Group type: EXPERIMENTAL
Intervention: GDFT
Number of subjects: 60
Study 30974240 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex training (n=18)
Number of subjects: 54
Study 30974240 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple training (n=17)
Number of subjects: 54
Study 30974240 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (n=19)
Number of subjects: 54
Study 29292264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 124
Study 29292264 — intervention group
Group type: COMPARATOR
Intervention: Control (single anesthetic agent)
Number of subjects: 124
Study 25877225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² for level 1 and 1200 mg/m² for level 2 on day 1), Cisplatin (30 mg/m² fixed dose on day 1), S-1 (40-60 mg/day fixed dose twice a day for 7 days), every 2 weeks until progression
Number of subjects: 18
Study 23571166 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of AS03‐adjuvanted H1N1 2009 vaccine (3.75 µg Hemagglutinin antigen)
Number of subjects: 240
Study 23571166 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of AS03‐adjuvanted H1N1 2009 vaccine (3.75 µg Hemagglutinin antigen, 21 days apart)
Number of subjects: 240